NASDAQ:CMRXChimerix Stock Price, Forecast & News

Chimerix's stock was trading at $1.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CMRX stock has increased by 0.0% and is now trading at $1.44. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chimerix.

Chimerix is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Chimerix.

Chimerix Inc (NASDAQ:CMRX) posted its quarterly earnings results on Tuesday, February, 25th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.11. The biopharmaceutical company earned $1.85 million during the quarter, compared to analyst estimates of $1.50 million. Chimerix had a negative net margin of 899.68% and a negative return on equity of 35.56%. View Chimerix's earnings history.

2 brokerages have issued 12 month target prices for Chimerix's stock. Their forecasts range from $3.00 to $7.00. On average, they anticipate Chimerix's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 247.2% from the stock's current price. View analysts' price targets for Chimerix.

Media headlines about CMRX stock have trended very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Chimerix earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutChimerix.

Chimerix saw a increase in short interest in March. As of March 13th, there was short interest totaling 1,913,600 shares, an increase of 35.7% from the February 27th total of 1,410,000 shares. Based on an average daily volume of 536,200 shares, the days-to-cover ratio is presently 3.6 days. Approximately 4.2% of the company's stock are short sold. View Chimerix's Current Options Chain.

Some companies that are related to Chimerix include Mirum Pharmaceuticals (MIRM), Beyondspring (BYSI), Viking Therapeutics (VKTX), NewLink Genetics (NLNK), Kala Pharmaceuticals (KALA), Organogenesis (ORGO), Trillium Therapeutics (TRIL), Crinetics Pharmaceuticals (CRNX), Merus (MRUS), Gemphire Therapeutics (GEMP), Avadel Pharmaceuticals (AVDL), Syros Pharmaceuticals (SYRS), DURECT (DRRX), Axovant Sciences (AXON) and OrganiGram (OGI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Wynn Resorts (WYNN), SLS International (SLS), Gilead Sciences (GILD), Walmart (WMT) and TherapeuticsMD (TXMD).

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Chimerix's stock is owned by many different retail and institutional investors. Top institutional investors include Marquette Asset Management LLC (0.06%). Company insiders that own Chimerix stock include Ernest Mario, Fred A Middleton, Garrett Nichols, M Michelle Berrey, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer. View institutional ownership trends for Chimerix.

CMRX stock was acquired by a variety of institutional investors in the last quarter, including Marquette Asset Management LLC. Company insiders that have bought Chimerix stock in the last two years include Fred A Middleton, M Michelle Berrey, Martha J Demski, Michael A Sherman, Michael T Andriole, and Robert J Meyer. View insider buying and selling activity for Chimerix.

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CMRX stock can currently be purchased for approximately $1.44.

Chimerix has a market capitalization of $88.91 million and generates $12.52 million in revenue each year. The biopharmaceutical company earns $-112,580,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Chimerix employs 82 workers across the globe. View additional information about Chimerix.

The official website for Chimerix is http://www.chimerix.com/.

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]